BRPI0409796A - uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina - Google Patents

uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina

Info

Publication number
BRPI0409796A
BRPI0409796A BRPI0409796-3A BRPI0409796A BRPI0409796A BR PI0409796 A BRPI0409796 A BR PI0409796A BR PI0409796 A BRPI0409796 A BR PI0409796A BR PI0409796 A BRPI0409796 A BR PI0409796A
Authority
BR
Brazil
Prior art keywords
thrombin
treatment
dipyridamole
mopidamole
prevention
Prior art date
Application number
BRPI0409796-3A
Other languages
English (en)
Inventor
Wolfgang Eisert
Victor L Serebruany
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI0409796A publication Critical patent/BRPI0409796A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE DIPIRIDAMOL OU MOPIDAMOL PARA TRATAMENTO E PREVENçãO DE DOENçAS TROMBOEMBOLìTICAS E DISTúRBIOS PROVOCADOS PELA FORMAçãO EXCESSIVA DE TROMBINA E/OU PELA EXPRESSãO ELEVADA DE RECEPTORES DE TROMBINA". A presente invenção refere-se a um método de tratamento do corpo de animal humano ou não-humano para tratar ou prevenir distúrbios provocados por elevada trombina ou elevada expressão de receptor de trombina, por exemplo, síndromes de doenças tromboembólicas vasculares, ou doenças proliferativas, cujo método compreende administrar ao corpo de um animal humano ou não-humano que necessite de semelhante tratamento uma quantidade eficaz de uma composição farmacêutica contendo dipiridamol, mopidamol ou um sal farmaceuticamente aceitável dos mesmos, composições farmacêuticas correspondentes bem como a aplicação de dipiridamol ou mopidamol para a fabricação destas composições farmacêuticas.
BRPI0409796-3A 2003-04-24 2004-04-17 uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina BRPI0409796A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46516803P 2003-04-24 2003-04-24
PCT/EP2004/004097 WO2004093881A2 (en) 2003-04-24 2004-04-17 Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors

Publications (1)

Publication Number Publication Date
BRPI0409796A true BRPI0409796A (pt) 2006-05-30

Family

ID=33311001

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409796-3A BRPI0409796A (pt) 2003-04-24 2004-04-17 uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina

Country Status (12)

Country Link
US (3) US20050014770A1 (pt)
EP (2) EP2062580A1 (pt)
JP (1) JP2006524203A (pt)
KR (1) KR20060007034A (pt)
CN (1) CN1812792A (pt)
AU (1) AU2004231306A1 (pt)
BR (1) BRPI0409796A (pt)
CA (1) CA2523157A1 (pt)
MX (1) MXPA05011432A (pt)
RU (1) RU2005136383A (pt)
WO (1) WO2004093881A2 (pt)
ZA (1) ZA200508016B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
EP1747016A2 (en) 2004-05-13 2007-01-31 Boehringer Ingelheim International GmbH Use of dipyridamole for treatment of resistance to platelet inhibitors
WO2006045756A1 (en) * 2004-10-25 2006-05-04 Boehringer Ingelheim International Gmbh Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005028168B3 (de) 2005-06-17 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Einrichtung zur Führung eines Gases für Vorrichtungen zum Behandeln körnigen Gutes durch Trocknen, Filmcoaten oder Beschichten, insbesondere Zulufteinheit und Vorrichtung mit einer derartigen Einrichtung
CA2657269A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors
JP2009543844A (ja) * 2006-07-17 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 直接トロンビン阻害剤の新しい小児適応症
CA2657266A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors in the cardiovascular field
WO2009080301A1 (en) * 2007-12-21 2009-07-02 Boehringer Ingelheim International Gmbh Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke
US20110306640A1 (en) * 2008-08-19 2011-12-15 Boehringer Ingelheim International Gmbh Dabigatran in tumour therapy
EP2358367A1 (en) * 2008-11-11 2011-08-24 Boehringer Ingelheim International GmbH Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
WO2011085473A1 (en) * 2010-01-13 2011-07-21 Linda Penn Treating cancer with statins and compounds having dipyridamole activity
CA3034874A1 (en) * 2015-10-15 2017-04-20 Moshe Rogosnitzky Low dose oral dipyridamole compositions and uses thereof
US20210277357A1 (en) * 2018-06-15 2021-09-09 Naing Bijaj Methods of detection of mechanically-activated platelet activation and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031450A (en) 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
GB1051218A (pt) 1963-03-09
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3237575A1 (de) 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
DE4035961A1 (de) 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US20020048599A1 (en) 2000-10-20 2002-04-25 Thomas H. Mueller Method for increasing tissue perfusion by co-administration of an agent that increases cGMP synthesis and an agent that inhibits cGMP degradation
JP2004518688A (ja) * 2001-01-30 2004-06-24 ブリストル−マイヤーズ　スクイブ　カンパニー ファクターＸａ阻害剤のスルホンアミドラクタムおよびその方法
EP1250921A1 (en) 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
US20030100493A1 (en) * 2001-07-19 2003-05-29 Sol Weiss Sublingual use of inhibitors in the biosynthesis of cholesterol
EP1308179A1 (en) * 2001-10-30 2003-05-07 Boehringer Ingelheim Pharma GmbH & Co.KG Improved endoprosthetic device
US20030180282A1 (en) * 2002-03-25 2003-09-25 Victor Serebruany Method of treatment of thrombotic events
CA2496445A1 (en) * 2002-08-14 2004-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
CN1747734A (zh) * 2003-02-07 2006-03-15 贝林格尔·英格海姆国际有限公司 潘生丁或单哌潘生丁在治疗和预防mmp－9－依赖性疾病中的用途

Also Published As

Publication number Publication date
CN1812792A (zh) 2006-08-02
EP2062580A1 (en) 2009-05-27
ZA200508016B (en) 2007-03-28
JP2006524203A (ja) 2006-10-26
EP1622621A2 (en) 2006-02-08
US20050014770A1 (en) 2005-01-20
RU2005136383A (ru) 2007-06-10
US20070105753A1 (en) 2007-05-10
US20090192123A1 (en) 2009-07-30
WO2004093881A2 (en) 2004-11-04
CA2523157A1 (en) 2004-11-04
MXPA05011432A (es) 2006-03-21
KR20060007034A (ko) 2006-01-23
AU2004231306A1 (en) 2004-11-04
WO2004093881A3 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
BRPI0409796A (pt) uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
WO2005051429A3 (en) Targeted conjugates with a modified saccharide linker
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
BRPI0606996A2 (pt) combinação de compostos orgánicos, uso da mesma e composição farmacêutica
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
BR0011823A (pt) Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
MX348705B (es) Composiciones farmacéuticas y métodos de administración relacionados.
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
BRPI0607536A2 (pt) tratamento de dor
BRPI0415167A (pt) composto de amina como ligandos de canal de ìon e usos dos mesmos
AR060089A1 (es) Tratamiento del dolor
BRPI0417959A (pt) anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável
BR0316906A (pt) administração do capsaicinoides
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
MX2009002054A (es) Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis.
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
IL128723A0 (en) Pharmaceutical compositions containing rar antagonists and rxr agonists
BR0316364A (pt) Combinação de terapia do câncer com um composto anticâncer ativado com gst e uma outra terapia anticâncer
BRPI0515261A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.